Pulmonary artery pressure

was significantly reduced in group. 1 & 3 patients (P < 0.0001, Table 2). The comparison of changes in all the above parameters between the three groups was statistically significant (p < 0.01 for all) ( Table 2). Only 43 patients out of 93 were having significant diastolic dysfunction. When comparing the E/A ratio, diastolic score and deceleration time it was seen that all the three were almost similar to baseline in all the treatment groups except the patients in group 3 deceleration time was significantly increased (P < 0.001) and the diastolic score was significantly decreased in the group 3 patients (P < 0.01) suggesting improved diastolic function. ( Table 2) whereas a slight increase of deceleration time and decrease in diastolic score was observed in the group 2 patients receiving only T. arjuna treatment. GW-572016 in vitro (P < 0.05) ( Table 2). Mitral valve regurgitation was significantly reduced in group 1 & 3 patients (P < 0.001& P < 0.0001) respectively. Myocardial performance index (MPI) for left ventricle could be calculated for only 10 patients in group 3 (0.41 ± 0.03). Because of some constraints in calculation MPI comparison could not be made, however the last recordings and calculations

definitely points towards a better Tei index in the group 3 patients and predicts favourable effect of the group 3 treatment. In the group 3 patients 41.9% (13) had a reduction in diastolic score, 38% (12) had no change and 20% (6) had 4-Aminobutyrate aminotransferase increase in diastolic score from the baseline. At the end of the study period 64.5% (20) patients in group 1 remained in the same functional class and 34.5% (11) Imatinib chemical structure increased their functional class suggesting worsening

of clinical status. In the group 2 patients 58% (18) remained in their functional class and 42%(13) increased their functional class. In the group 3, 64.5% (20) patients remained in their functional class, 16.1%(5) patients decreased their functional class from III to II and 19.4% (6) patients increased their functional class. This is reflected in the number of hospitalizations as reported in Table 3. The main findings of this study is that the patients of dilated cardiomyopathy with mild to moderately reduced functional capacity and in stable condition if treated with T. arjuna along with the standard. Therapy for a period of 2 years can satisfactorily improve the systolic and diastolic functions of the heart. Apart from improvement in the ejection fraction there is a significant reduction in the ventricular systolic and diastolic diameters and in the degree of mitral regurgitation. Reduction in the pulmonary artery pressure measured during systole (tricuspid valve gradient) contributes to the improvement in the diastolic functions. The systolic and diastolic blood pressure as well as the NYHA functional class seems to be favourably affected by the combination of the standard treatment plus the standardized T. arjuna treatment.